Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. [electronic resource]
Producer: 20150127Description: 3145-52 p. digitalISSN:- 1879-0852
- Administration, Oral
- Aged
- Antineoplastic Agents -- administration & dosage
- Benzimidazoles -- administration & dosage
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Mutation -- genetics
- Neoplasm Metastasis
- Quinolones -- administration & dosage
- Receptor, Fibroblast Growth Factor, Type 3 -- genetics
- Treatment Outcome
- Urologic Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.